AR026022A1 - Metodo para el tratamiento de la obesidad - Google Patents
Metodo para el tratamiento de la obesidadInfo
- Publication number
- AR026022A1 AR026022A1 ARP000105369A ARP000105369A AR026022A1 AR 026022 A1 AR026022 A1 AR 026022A1 AR P000105369 A ARP000105369 A AR P000105369A AR P000105369 A ARP000105369 A AR P000105369A AR 026022 A1 AR026022 A1 AR 026022A1
- Authority
- AR
- Argentina
- Prior art keywords
- obesity
- treatment
- solvatofarma
- animal
- pharmaceutically acceptable
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 206010056465 Food craving Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 230000003880 negative regulation of appetite Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Método para el tratamiento de la obesidad que comprende administrar a un animal que necesite del mismo, un compuesto de formula (1) o una sal o solvatofarmacéuticamente aceptable del mismo. Los métodos para la supresion del apetito, para causarpérdi da de peso, para prevenir el aumento de peso, para afectarpreferencialmente la composicion grasa del cuerpo, para inhibir el antojo del alimento, o para mantener el peso bajo también se describen.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9924275.2A GB9924275D0 (en) | 1999-10-13 | 1999-10-13 | Method for the treatment of obesity |
GB0001861A GB0001861D0 (en) | 2000-01-28 | 2000-01-28 | Method for the treatment of obesity |
Publications (1)
Publication Number | Publication Date |
---|---|
AR026022A1 true AR026022A1 (es) | 2002-12-26 |
Family
ID=26243494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000105369A AR026022A1 (es) | 1999-10-13 | 2000-10-12 | Metodo para el tratamiento de la obesidad |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1220673A2 (es) |
JP (1) | JP2003511410A (es) |
AR (1) | AR026022A1 (es) |
AU (1) | AU7750100A (es) |
PE (1) | PE20010744A1 (es) |
WO (1) | WO2001026641A2 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1414518A4 (en) | 2001-08-08 | 2009-01-21 | Kevin R Orton | APPARATUS AND METHOD FOR ELECTRICAL CONDUCTION SLIMMING |
WO2003097046A1 (en) | 2002-05-17 | 2003-11-27 | Duke University | Method for treating obesity |
PT2316456T (pt) | 2003-04-29 | 2017-09-05 | Orexigen Therapeutics Inc | Composições para afetar a perda de peso compreendendo naltrexona e bupropion |
WO2007067341A2 (en) | 2005-11-22 | 2007-06-14 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
AU2007319472B2 (en) | 2006-11-09 | 2013-01-17 | Nalpropion Pharmaceuticals Llc | Methods Of Administering Weight Loss Medications |
JP2011506298A (ja) * | 2007-12-05 | 2011-03-03 | アストラゼネカ アクチボラグ | 新規化合物iv |
EP2303025A4 (en) | 2008-05-30 | 2012-07-04 | Orexigen Therapeutics Inc | METHOD FOR TREATING DIGITAL FAT SWITCHES |
CA2726646A1 (en) * | 2008-06-04 | 2009-12-10 | Astrazeneca Ab | New compounds vii |
JP6196041B2 (ja) | 2010-01-11 | 2017-09-13 | オレキシジェン・セラピューティクス・インコーポレーテッド | 大うつ病を有する患者において減量療法を提供する方法 |
RS60682B1 (sr) | 2012-06-06 | 2020-09-30 | Nalpropion Pharmaceuticals Llc | Kompozicija za upotrebu u postupku lečenja prekomerne težine i gojaznosti kod pacijenata sa visokim kardiovaskularnim rizikom |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8924528D0 (en) * | 1989-10-31 | 1989-12-20 | Wellcome Found | Heterocyclic pharmaceutical compounds,preparation and use |
AU744261B2 (en) * | 1997-04-24 | 2002-02-21 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating eating disorders |
WO1999025355A1 (en) * | 1997-11-14 | 1999-05-27 | Glaxo Group Ltd. | Method of treating addiction to nicotine products |
NZ529316A (en) * | 1998-01-21 | 2004-05-28 | Glaxo Group Ltd | Pharmaceutically active morpholinol |
MA26693A1 (fr) * | 1998-09-28 | 2004-12-20 | Glaxo Group Ltd | Compositions pour administration par voie buccale |
-
2000
- 2000-10-03 WO PCT/US2000/027252 patent/WO2001026641A2/en not_active Application Discontinuation
- 2000-10-03 EP EP00967281A patent/EP1220673A2/en not_active Withdrawn
- 2000-10-03 AU AU77501/00A patent/AU7750100A/en not_active Abandoned
- 2000-10-03 JP JP2001529431A patent/JP2003511410A/ja active Pending
- 2000-10-11 PE PE2000001089A patent/PE20010744A1/es not_active Application Discontinuation
- 2000-10-12 AR ARP000105369A patent/AR026022A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU7750100A (en) | 2001-04-23 |
JP2003511410A (ja) | 2003-03-25 |
WO2001026641A2 (en) | 2001-04-19 |
EP1220673A2 (en) | 2002-07-10 |
WO2001026641A3 (en) | 2002-01-10 |
PE20010744A1 (es) | 2001-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2024007720A (es) | Lipidos para la administracion de agentes activos en nanoparticulas lipidicas. | |
KR950010890A (ko) | 폐경기 증후군의 치료방법 | |
CY1105000T1 (el) | Χρηση της σπινοσαδης ή μιας συνθεσεως περιεχουσης σπινοσαδη | |
CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
AR030933A1 (es) | Derivados del triazol y composiciones farmaceuticas que los contienen | |
DOP2004001052A (es) | Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1 | |
KR930003912A (ko) | 울혈성 심장 마비 치료법 | |
CL2023000196A1 (es) | Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos | |
CO5251429A1 (es) | Derivados de ter-butil-(7-metil-imidazo(1,2-a)piridin-3- il)-amina procedimiento para su preparacion, medicamentos que los contienen, su uso para la preparacion de un medicamento para la inhibicion de la no-sintasa y composiciones farmaceuticas que l | |
KR930019637A (ko) | 비페닐설포닐우레아 또는 비페닐설포닐우레탄 측쇄를 갖는 이미다졸 유도체, 이의 제조방법 및 용도 | |
PA8591701A1 (es) | Derivados de pirrolopirimidina | |
CY1109242T1 (el) | Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου | |
AR026022A1 (es) | Metodo para el tratamiento de la obesidad | |
UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
CR7510A (es) | DERIVADOS DE [1-4] DIAZEPINO[6,7,1-iJ)] QUINOLONA COMO AGENTES ANTIPSICOTICOS Y CONTRA LA OBESIDAD | |
CY1106763T1 (el) | Προληπτικα ή θεραπευτικα μεσα για φλεγμονωδεις νοσους του εντερου | |
PL356252A1 (en) | Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist | |
TR200102646T2 (tr) | Yeme bozukluklarının tedavi edilmesi. | |
WO2005030766A8 (en) | Phenyl - carboxamide compounds useful for treating pain | |
AR039190A1 (es) | Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto | |
TR200101633T2 (tr) | Farmasötik bileşim | |
CO5200778A1 (es) | Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis | |
AR014964A1 (es) | Derivados de indol, composiciones farmaceuticas que los contienen, agentes para reducir la presion intraocular, tratar glaucoma e hipertension ocular, usosen la fabricacion de composiciones farmaceuticas y procedimiento de fabricacion de dichas composiciones | |
RU2019121690A (ru) | Дексмедетомидин или медетомидин для применения для лечения сепарационной тревожности у собак | |
AU2002357191A1 (en) | Derivatives of isoindigo, indigo and indirubin and use in treating cancer |